Clinical and Translational Studies: Office of Psychiatric Research

The Office of Psychiatric Clinical Research is designed to support psychiatric research in the clinical setting here at the Department of Psychiatry and Behavioral Neurobiology.  Our research division offers several cutting edge resources for Phase II, III and IV studies.  The coordination of our clinical trials is of the highest quality.  We are supported by experienced investigators and staff dedicated to academic excellence and quality patient care.  We have a full-time clinical research staff with regulatory and administrative services and assistance in designing clinical studies and providing referrals for statistical analysis.  We provide investigator training in psychiatric rating scales and standardized diagnostic instruments and education in patient recruitment.  We have a quality assurance program and facilities for drug storage, physical exams, EKG’s, interviewing, venipuncture and specimen processing. 

Our expert research team consists of:

Hollis Ryan, BS, CCRC – Clinical Trials Manager; Samantha White, BS – Clinical Trials Administrator; Emily Bruer, M.Ed. – Clinical Trials Specialist; Nick Bossaller, BA – Clinical Trials Specialist; Brittanie Muse, BS – Research Technician; Rachel Chassan, M.S. - Research Assistant; Roberta May, MA, CCRC – Associate Professor

Currently Enrolling Trials:

 Mood Disorders

" Oxidative Stress Mechanisms in Mood Disorders" Principal Investigator: Richard Shelton, MD

" Early life origins of obesity: the relationships between early life stress and abdominal obesity in depressed patients" Principal Investigator: Li Li, MD, PhD

"Double-Blind, Proof-of-Concept (POC) Trial of Low Field Magnetic Stimulation (LFMS) Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD) (Parent Study: Rapidly-Acting Treatments for Treatment Resistant Depression)" Principal Investigator: Richard Shelton, MD

“ALK5461-207: A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-5 Study)” Principal Investigator: Richard Shelton, MD

“ALK5461-208: A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)” Principal Investigator: Richard Shelton, MD

LVM-MD-15: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse-Prevention Study with Levomilnacipran ER in Patients With Major Depressive Disorder” Principal Investigator: Richard Shelton, MD

“Do Micro RNAs Link Diabetes with Depression and Suicide?” Principal Investigator: Richard Shelton, MD, Yogesh Dwivedi, Ph. D.

"A double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of intranasal esketamine for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to be at imminent risk for suicide" Principal Investigator: Richard Shelton, MD

“A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects With Major Depressive Disorder Who Have Responded to Antidepressant Treatment” Principal Investigator: Richard Shelton, MD

Other Enrolling Studies

"Psychiatric Biological Samples Repository" Principal Investigator: Richard Shelton, MD

Not Currently Enrolling

" A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy in the Treatment Acute Depressive Episodes Associated with Bipolar 1 Disorder in Adult Subjects (TAK375SL_201)" Principal Investigator: Richard Shelton, MD

" A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects (TAK375SL_203)" Principal Investigator: Richard Shelton, MD

"A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering from a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode – an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic" Principal Investigator: Richard Shelton, MD
 
"Circadian Misalignment in Shift Work Nurses" Principal Investigator: Karen Gamble, PhD

“A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deuterium modified dextromethorphan hydrobromide/quinidine sulfate) as an adjunctive therapy in patients with major depressive disorder with an inadequate response to antidepressant treatment” Principal Investigator: Richard Shelton, MD

“ Phase 2, Open Label Extension for Subjects with Inadequate/Partial Response to Antidepressants during the Current Episode of Major Depressive Disorder Previously Treated with GLYX13 (Extension of GLYX13-C-202, NCT0184163)” Principal Investigator: Richard Shelton, MD

Healthy Volunteers

We have some studies that require Healthy Volunteers. Please contact us to find out what we have available.  

 

For further information, please contact:
UAB Department of Psychiatry
Office of Psychiatric Clinical Research
1720 7th Avenue South
Sparks Building, 10th Floor
Birmingham, AL 35294-0017
Telephone:  (205) 934-2484
Email: psychresearch@uab.edu